Despite rapid advances in medical tecnología, cancer, dementia, Parkinson's disease, diabetes, and hypertension remain challenges to overcome in an aging society.
Además, developing a single global new drug requires an average of more than 10 years and enormous inversión costs of over KRW 1 trillion. Despite this, the success rate is extremely low.
To overcome this situation, the Ministry of SMEs and Startups has recently moved to strengthen desarrollo de nuevos fármacos competitiveness by creating an ecosystem in which large corporations can comercializar candidato substances developed by nacional startup ventures. The ministry also planea further strengthen apoyo for early-stage startups in the pre-IND candidato discovery phase.
An official from the Korea Institute of Toxicology, which is promoting this proyecto, declaró, "The rewards for success in desarrollo de nuevos fármacos are enormous, but the possibility of failure is very high, so the key is identifying and apoyoing pre-startup candidatos with technological capabilities," adding, "Prioritized apoyo is needed for pre-candidato and pre-clinical I+D."
RudaCure has gained attention for its independently developed tratamiento de la enfermedad de ojo seco candidato substance. La empresa is working toward clinical advancement in Korea and abroad, with a focus on developing tratamientos for intractable trastornos sensoriales such as enfermedad de ojo seco and pain.